Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Blinding01:11

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
The Stanford Prison Experiment03:20

The Stanford Prison Experiment

The famous and controversial Stanford Prison Experiment, conducted by social psychologist Philip Zimbardo and his colleagues at Stanford University, demonstrated the power of social roles, social norms, and scripts.
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Rational Emotive Behavior Therapy01:24

Rational Emotive Behavior Therapy

Cognitive-behavioral therapies (CBTs) are grounded in the belief that our thoughts profoundly influence our emotions and actions. Advocates of CBT emphasize three core assumptions: first, that cognitions are identifiable and measurable; second, that they are central to psychological functioning; and third, that irrational or maladaptive beliefs can be replaced with rational and adaptive ones. This transformative approach to therapy has paved the way for specific models such as Albert Ellis's...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Turning genes into medicines.

Nature medicine·2025
Same author

Roadmap for direct and indirect translation of optogenetics into discoveries and therapies for humans.

Nature neuroscience·2025
Same author

Fidanacogene Elaparvovec for Hemophilia B - A Multiyear Follow-up Study.

The New England journal of medicine·2025
Same author

Gene therapy for hemophilia - From basic science to first approvals of "one-and-done" therapies.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

Validation of a quantitative cell-based relative potency assay for LUXTURNA.

Molecular therapy. Methods & clinical development·2025
Same author

Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy.

The New England journal of medicine·2024
Same journal

Tracking Synthetic Adhesins on Bacterial Surfaces with Immunofluorescence Microscopy.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Post-Selection Methods for Analyzing mRNA Display Selections and Optimization of Hits.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

High-Performance Computing in Tandem Mass Spectrometry (MS/MS) Peptide Identification.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Engineering and Adapting Disulfide-Containing Proteins to Enable Intracellular Functionality.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

AI-Driven Protein Research: From Prediction to Design.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Methods for the In Vitro Selection of Protein and Peptide Libraries Using mRNA Display.

Methods in molecular biology (Clifton, N.J.)·2026
See all related articles

Related Experiment Video

Updated: May 28, 2026

Human Fear Conditioning Conducted in Full Immersion 3-Dimensional Virtual Reality
10:38

Human Fear Conditioning Conducted in Full Immersion 3-Dimensional Virtual Reality

Published on: August 9, 2010

rAAV human trial experience.

Katherine A High1, Patrick Aubourg

  • 1Howard Hughes Medical Institute, Philadelphia, PA, USA. high@email.chop.edu

Methods in Molecular Biology (Clifton, N.J.)
|October 29, 2011
PubMed
Summary
This summary is machine-generated.

Recombinant adeno-associated virus (AAV) vectors show promise in treating genetic disorders like Leber

More Related Videos

A Method for Remotely Silencing Neural Activity in Rodents During Discrete Phases of Learning
09:22

A Method for Remotely Silencing Neural Activity in Rodents During Discrete Phases of Learning

Published on: June 22, 2015

SSVEP-based Experimental Procedure for Brain-Robot Interaction with Humanoid Robots
11:01

SSVEP-based Experimental Procedure for Brain-Robot Interaction with Humanoid Robots

Published on: November 24, 2015

Related Experiment Videos

Last Updated: May 28, 2026

Human Fear Conditioning Conducted in Full Immersion 3-Dimensional Virtual Reality
10:38

Human Fear Conditioning Conducted in Full Immersion 3-Dimensional Virtual Reality

Published on: August 9, 2010

A Method for Remotely Silencing Neural Activity in Rodents During Discrete Phases of Learning
09:22

A Method for Remotely Silencing Neural Activity in Rodents During Discrete Phases of Learning

Published on: June 22, 2015

SSVEP-based Experimental Procedure for Brain-Robot Interaction with Humanoid Robots
11:01

SSVEP-based Experimental Procedure for Brain-Robot Interaction with Humanoid Robots

Published on: November 24, 2015

Area of Science:

  • Gene Therapy
  • Viral Vector Technology
  • Clinical Trials

Background:

  • Recombinant adeno-associated virus (AAV) vectors have been utilized in clinical research since the mid-1990s.
  • Over 300 subjects have participated in AAV vector-based clinical trials.
  • AAV vectors demonstrate a robust safety profile following local and systemic administration.

Purpose of the Study:

  • To review clinical efficacy studies utilizing recombinant AAV vectors.
  • To discuss safety considerations and potential risks associated with AAV gene therapy.
  • To detail methodologies for monitoring vector DNA and immune responses.

Main Methods:

  • Review of clinical trial data for Leber's congenital amaurosis and Parkinson's disease.
  • Analysis of gene therapy studies for hemophilia.
  • Description of quantitative PCR for vector DNA detection and IFN-γ assays for immune response.

Main Results:

  • Demonstrated clinical efficacy of AAV vectors in Leber's congenital amaurosis and Parkinson's disease.
  • Short-term efficacy in hemophilia gene therapy, with transient expression potentially due to immune response.
  • Discussion of safety events, including a single death (unrelated to AAV), integration risks, and immune responses.

Conclusions:

  • Recombinant AAV vectors have shown clinical efficacy in specific genetic disorders.
  • Safety is generally good, but potential risks like immune responses and vector DNA persistence require careful monitoring.
  • Established protocols exist for safety monitoring in AAV gene therapy trials.